Tag: KURA

Blue Horseshoe Stocks: Options, NLNK Recaps & More

GoPro, Inc. GPRO

We took advantage of the situation with GPRO yesterday after noticing the stock light up the boards in the premarket on the heels of a guidance adjustment.

We set our sights on the GPRO Weekly $9.50 & $10 Calls and both sets of contracts ended up providing traders with a chance at notable intraday gains.

The $9.50’s ran from .13-.90 for a whopping intraday pop of 592%, while the $10’s traded in a range from .47-1.20 for chances at up to 155% profit.


Insmed, Inc. INSM – Update

We’ve also got the pleasure of updating the figures on the options idea we put out on Tuesday after INSM had yet another solid session. The updated ranges on the contracts we selected are quite impressive, including a twelve-bagger, clearly demonstrating why we devote so much energy to options trading in addition to stocks!

The gains that were up for grabs to anyone who was paying attention were as follows:

$27 Calls – Range: .95-4.50 – Max Gain: 373%
$28 Calls – Range:  .25-3.40 – Max Gain: 1260%
$29 Calls – Range: .40-2.75 – Max Gain: 588%
$30 Calls – Range: .50-2.12 – Max Gain: 324%

NewLink Genetics Corp. NLNK

We also had some very good fortune with our call of NLNK yesterday morning, which we caught notice of on our routine morning scan after some abnormal activity cropped up in the premarket.

Despite the fact that it went into the session as a $9+ stock, we still saw a really nice intraday push en route to NLNK going on the books as the NASDAQ’s top mover. We observed as the stock ran from a low of  9.50, traded up for essentially the entire session, and hit a high of 14.48 for a hefty 52% move on the day.

NLNK closed with strength, maintaining well over half its daily advance, so we’ll definitely want to continue to monitor the situation. No matter how you slice it, a single-session gain of 50% from a nearly ten-dollar stock, is nothing short of incredible.

Extended Watchlist:
CLDR, KURA, AVEO, OPGN, EPIX, FUTL,
FRTA(Bottom-Bouncer)

Blue Horseshoe Stocks: Updates, Fresh Plays & More

Kraig Biocraft Laboratories, Inc. KBLB

We alerted KBLB in Wednesday morning’s premarket report, and on that day, we would observe a PPS low of .0261. Yesterday, the stock hit a high of .0395, for a respectable two-session upswing of 51%

Following that solid run-up, we saw the stock close at .0375, maintaining a vast majority of its advance. We’ll continue to keep a steady eye on KBLB, and look for it to maintain support above the .03-mark in order to keep us interested.

Potential Bottom-Plays

Rennova Health, Inc. RNVA – We have an interesting story unfolding with RNVA, and a potential rebound opportunity as well. After briefly cracking its 50DMA on Wednesday, the stock took a major gut punch yesterday as it gapped down immensely.

It seems a bit of an overreaction after reading the PR that apparently catalyzed the selloff. The company announced yesterday that it had priced a public offering with the intent of raising upwards of $8.6M in capital, expected to close by Tuesday. They set the purchase price at .45, which is why a massive slide to less than .30 seemed disproportionate.

We’ll be interested to see the activity in this now majorly-oversold stock in sessions to come.


__________

Ampio Pharmaceuticals, Inc. AMPE – Speaking of stocks that have recently gapped down hard and found new lows, we have AMPE hitting our bottom-play radar.

Similar to the aforementioned play, the selloff occurred as a result of what some might construe as over-reactive. The company released data from a clinical study at the end of last month on its osteoarthritis injection treatment that was poorly-received.  However, while the primary endpoints of the double-blind study were not met, the treatment was markedly effective in improving the patients with the most extreme cases of the condition.

So the study was not a total loss, and the company made clear its intent to submit an FDA application for the treatment for those severely afflicted patients that were helped, and for whom no other non-surgical alternative exists.

That’s why we’ll be keeping an eye on AMPE to continue to regain some of its lost ground, as it has done over the past few sessions.

Extended Watchlist:
MAXD, MFST, PPHM, FES, SPU, KURA, COSI(Bottom watch)